Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like T*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description drug_category drug_category_source wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020018030 ALUNBRIG 180 MG TABLET * 30 PACK Brand FDA 01/04/2023 1251.00 19121.00 11/10/2035 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020011330 ALUNBRIG 30 MG TABLET * 30 PACK Brand FDA 01/04/2023 418.00 6377.00 11/10/2035 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020009030 ALUNBRIG 90 MG TABLET * 30 PACK Brand FDA 01/04/2023 1251.00 19121.00 11/10/2035 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020009007 ALUNBRIG 90 MG TABLET * 7 PACK Brand FDA 01/04/2023 292.00 4463.00 11/10/2035 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020019830 ALUNBRIG INITIATION PACK - 7 CT 90 MG TABLET and 23 CT 180 MG TABLET - PER PACK Brand FDA 01/04/2023 1251.00 19121.00 11/10/2035 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 64764030020 Entyvio 300mg 20mL Vial Brand FDA 01/01/2023 462.79 8176.02 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020053630 ICLUSIG 10 MG TABLET * 30 PACK Brand FDA 01/04/2023 1317.00 20126.00 12/12/2033 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020053530 ICLUSIG 15 MG TABLET * 30 PACK Brand FDA 01/04/2023 1317.00 20126.00 12/12/2033 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020053330 ICLUSIG 30 MG TABLET * 30 PACK Brand FDA 01/04/2023 1317.00 20126.00 12/12/2033 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020053430 ICLUSIG 45 MG TABLET * 30 PACK Brand FDA 01/04/2023 1317.00 20126.00 12/12/2033 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020023002 NINLARO 2.3 MG CAPSULE * 3 PACK Brand FDA 01/04/2023 801.00 12240.00 11/20/2029 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020023001 NINLARO 2.3 MG CAPSULE * SINGLE PACK Brand FDA 01/04/2023 268.00 4083.00 11/20/2029 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020039002 NINLARO 3.0 MG CAPSULE * 3 PACK Brand FDA 01/04/2023 801.00 12240.00 11/20/2029 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020039001 NINLARO 3.0 MG CAPSULE * SINGLE PACK Brand FDA 01/04/2023 268.00 4083.00 11/20/2029 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020040002 NINLARO 4.0 MG CAPSULE * 3 PACK Brand FDA 01/04/2023 801.00 12240.00 11/20/2029 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105 Takeda Pharmaceuticals America, Inc. 03/31/2023 63020040001 NINLARO 4.0 MG CAPSULE * SINGLE PACK Brand FDA 01/04/2023 268.00 4083.00 11/20/2029 Single Source Drug None 1 None 1 NA None None None None None None None None None None None Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000232 TerSera Therapeutics LLC 03/31/2023 70720012585 Xermelo Oral Tablet 250 MG Package Size 84 Package Quantity 1 Brand FDA 01/01/2023 785.27 8717.34 None Single Source Drug None 1 None 1 None 1 09/08/2020 Lexicon Pharmaceuticals, Inc 159000000 None Lexicon received approximately $159M in upfront payments and up to $65 million in future milestone payments plus mid-teens royalties on net sales of XERMELO for the treatment of biliary tract cancer. 6559.00 5961.00 2017 5164.00 None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232 TerSera Therapeutics LLC 03/31/2023 70720095036 Zoladex Subcutaneous Implant 3.6 MG Package Size 1 Quantity 1 Brand FDA 01/01/2023 77.58 861.19 None Single Source Drug None 1 None 1 None 1 04/06/2018 AztraZeneca 320000000 None AstraZeneca received a $250m upfront payment for the rights of Zoladex, with double-digit quarterly sales-based payments being recieved on an ongoing basis. A further $70m was also in the sell should Zoladex meet a series of sales-related milestones. 605.00 550.50 1989 265.63 None Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000302 Tetraphase Pharmaceuticals 03/31/2023 71773005012 XERAVA® (eravacycline) for injection, for intravenous use: 12 VIAL GLASS IN 1 CARTON > 1 INJECTION / POWDER / LYOPHILIZED / FOR SOLUTION IN 1 VIAL GLASS > 50 MG/1 VIAL Brand FDA 01/01/2023 48.00 684.00 10/19/2037 Innovator Multiple Source Drug None 1 The increase of Wholesale Acquisition Cost (WAC) for the product is due to financial and non-financial factors that include, but are not limited to, the rising costs of manufacturing, distribution, and marketing. None No change or improvement None None None None None None None None None None None None
Rx0000217 Teva Neuroscience, Inc. 03/31/2023 68546017260 AUSTEDO TABLETS 12MG 60 Brand FDA 01/01/2023 450.80 7080.70 09/15/2038 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217 Teva Neuroscience, Inc. 03/31/2023 68546017060 AUSTEDO TABLETS 6MG 60 Brand FDA 01/01/2023 300.60 4720.50 09/15/2038 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217 Teva Neuroscience, Inc. 03/31/2023 68546017160 AUSTEDO TABLETS 9MG 60 Brand FDA 01/01/2023 338.10 5310.50 09/15/2038 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217 Teva Neuroscience, Inc. 03/31/2023 68546014256 AZILECT TABLET 0.5MG 30 Brand FDA 01/01/2023 48.80 1045.30 08/27/2027 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217 Teva Neuroscience, Inc. 03/31/2023 68546022956 AZILECT TABLET 1MG 30 Brand FDA 01/01/2023 48.80 1045.30 08/27/2027 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844011001 ADDERALL TABLET 10MG 100 Generic FDA 01/01/2023 84.20 980.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844011201 ADDERALL TABLET 12.5MG 100 Generic FDA 01/01/2023 84.20 980.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844011501 ADDERALL TABLET 15MG 100 Generic FDA 01/01/2023 84.20 980.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844012001 ADDERALL TABLET 20MG 100 Generic FDA 01/01/2023 84.20 980.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844013001 ADDERALL TABLET 30MG 100 Generic FDA 01/01/2023 84.20 980.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844010501 ADDERALL TABLET 5MG 100 Generic FDA 01/01/2023 84.20 980.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844011701 ADDERALL TABLET 7.5MG 100 Generic FDA 01/01/2023 84.20 980.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844001901 ADIPEX-P CAPSULES 100 Brand Medispan 01/01/2023 21.78 253.48 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844014001 ADIPEX-P TABLETS 100 Generic FDA 01/01/2023 21.39 248.96 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844014056 ADIPEX-P TABLETS 30 Generic FDA 01/01/2023 4.97 57.83 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 63459070060 AMRIX ORAL CAPSULE ER 15 MG 60 Brand FDA 01/01/2023 148.70 3183.20 02/26/2025 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 63459070160 AMRIX ORAL CAPSULE ER 30 MG 60 Brand FDA 01/01/2023 148.70 3183.20 02/26/2025 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 63459054128 FENTORA TABLET 100MCG 28 Brand FDA 01/01/2023 94.00 2012.90 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 63459054228 FENTORA TABLET 200MCG 28 Brand FDA 01/01/2023 118.80 2543.20 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 63459054428 FENTORA TABLET 400MCG 28 Brand FDA 01/01/2023 172.40 3690.20 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 63459054628 FENTORA TABLET 600MCG 28 Brand FDA 01/01/2023 223.80 4790.80 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 63459054828 FENTORA TABLET 800MCG 28 Brand FDA 01/01/2023 275.70 5902.10 06/15/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 52544008001 FIORICET CAPSULE 50/300/40 MG 100 Generic FDA 01/01/2023 51.50 703.50 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 52544008201 FIORICET/CODEINE CAPSULE 50/300/40/30MG 100 Generic FDA 01/01/2023 107.80 1472.80 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 06/30/2023 00093360882 FLUTIC/SALMET INH PWD 113/14MCG 60 DOSE Generic FDA 05/19/2023 5.73 122.73 04/06/2035 Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years. This covered drug is an authorized generic (“AG”) version of AirDuo™ RespiClick®, a branded product also sold by Teva. Both the branded AirDuo™ RespiClick® product and the AG version of that same product, on which Teva is reporting here, simultaneously launched under the same NDA #208799 and thus are subject to the same patent expiration dates.
Rx0000019 Teva Pharmaceuticals USA 06/30/2023 00093360982 FLUTIC/SALMET INH PWD 232/14MCG 60 DOSE Generic FDA 05/19/2023 5.73 122.73 04/06/2035 Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years. This covered drug is an authorized generic (“AG”) version of AirDuo™ RespiClick®, a branded product also sold by Teva. Both the branded AirDuo™ RespiClick® product and the AG version of that same product, on which Teva is reporting here, simultaneously launched under the same NDA #208799 and thus are subject to the same patent expiration dates.
Rx0000019 Teva Pharmaceuticals USA 06/30/2023 00093360782 FLUTICA/SALMET INH PWD 55-14MCG 60 DOSE Generic FDA 05/19/2023 5.73 122.73 04/06/2035 Non-innovator Multiple Source Drug 0 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years. This covered drug is an authorized generic (“AG”) version of AirDuo™ RespiClick®, a branded product also sold by Teva. Both the branded AirDuo™ RespiClick® product and the AG version of that same product, on which Teva is reporting here, simultaneously launched under the same NDA #208799 and thus are subject to the same patent expiration dates.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844020852 GALZIN CAPSULE 50 MG 250 Brand FDA 01/01/2023 74.30 864.40 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 57844021552 GALZIN CAPSULE 25 MG 250 Brand FDA 01/01/2023 44.60 518.70 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 00575620030 PROGLYCEM ORAL SUSPENSION 50MG/ML 30ML/ 1 BOTTLE Brand FDA 01/01/2023 29.80 406.60 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019 Teva Pharmaceuticals USA 03/31/2023 63459017714 SYNRIBO INJECTIONS 3.5MG VIAL Brand Medispan 01/01/2023 114.40 1330.90 10/26/2026 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218 Teva Respiratory, LLC 03/31/2023 59310081206 AirDuo RespiClick 113/14 Inhalation Aerosol Powder Breath Activated 113-14 MCG/ACT Brand FDA 01/01/2023 18.80 402.10 04/06/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218 Teva Respiratory, LLC 03/31/2023 59310082206 AirDuo RespiClick 232/14 Inhalation Aerosol Powder Breath Activated 232-14 MCG/ACT Brand FDA 01/01/2023 18.80 402.10 04/06/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218 Teva Respiratory, LLC 03/31/2023 59310080506 AirDuo RespiClick 55/14 Inhalation Aerosol Powder Breath Activated 55-14 MCG/ACT Brand FDA 01/01/2023 18.80 402.10 04/06/2035 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218 Teva Respiratory, LLC 03/31/2023 59310040606 Qnasl Childrens Nasal Aerosol Solution 40 MCG/ACT Brand FDA 01/01/2023 13.80 295.53 10/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000218 Teva Respiratory, LLC 03/31/2023 59310041012 Qnasl Nasal Aerosol Solution 80 MCG/ACT Brand FDA 01/01/2023 13.80 295.53 10/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285013197 LOESTRIN 21 TABLET 1.0MG/20MCG 105 Generic FDA 01/01/2023 66.50 908.60 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285012797 LOESTRIN 21 TABLET 1.5MG/30MCG 105 Generic FDA 01/01/2023 66.50 908.60 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285012870 LOESTRIN FE TABLET 28 1.5MG/30MCG 140 Generic FDA 01/01/2023 66.50 908.60 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285012570 LOESTRIN FE TABLET 28 1MG/20MCG 140 Generic FDA 01/01/2023 66.50 908.60 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285012058 MIRCETTE TABLET 28 .15MG/.02MG .01MG Generic FDA 01/01/2023 99.20 1154.30 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285006390 PREFEST TABLET 1/1-0.09 MG 180 Generic FDA 01/01/2023 84.90 1159.60 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285043187 QUARTETTE TABLET 42-21-21-7 DAYS 182 Brand FDA 01/01/2023 110.20 1282.90 03/11/2029 Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285036801 TREXALL TABLET 10 MG 30 Generic FDA 01/01/2023 99.30 1156.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285036901 TREXALL TABLET 15 MG 30 Generic FDA 01/01/2023 149.00 1734.40 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285036601 TREXALL TABLET 5 MG 30 Generic FDA 01/01/2023 49.70 578.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285036701 TREXALL TABLET 7.5 MG 30 Generic FDA 01/01/2023 74.50 867.20 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285004001 ZIAC TABLET 10MG/6.25MG 30 Brand FDA 01/01/2023 23.20 270.20 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285004702 ZIAC TABLET 2.5MG/6.25MG 100 Brand FDA 01/01/2023 77.40 900.60 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219 Teva Women's Health, Inc. 03/31/2023 51285005002 ZIAC TABLET 5MG/6.25MG 100 Brand FDA 01/01/2023 77.40 900.60 None Innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000057 Theratechnologies Inc. 03/31/2023 62064024130 EGRIFTA SV 2MG LYO PWD 30/PAC Brand FDA 01/01/2023 454.00 6945.00 05/01/2023 Single Source Drug 0 1 None 1 None 1 None None None None None None None None None None Theratechnologies considers the process of assessing and developing price actions to be a trade secret using confidential information and cannot release this data into the public domain.
Rx0000207 Tolmar Pharmaceuticals, Inc. 12/31/2023 69087015812 Jatenza, 158 mg, 12 BOTTLES in 1 BOX, 120 Liquid Filled Capsules in 1 Bottle Brand FDA 12/09/2023 38.50 1001.15 04/12/2039 Single Source Drug 8176 None Tolmar utilizes a Pricing Committee which uses several factors to determine the price of our prescription medications.?? These include current market pricing competitiveness, existing and predicted future competition, manufacturing and distribution considerations (including distribution channel and payer model), costing including product development expenditures, profitability, and legal considerations, including compliance with rules and regulations governing sales to government and institutional purchasers.? The list price of Tolmar?s products is not reflective of discounts and rebates which may be available to patients and payers, including but not limited to, Medicaid and commercial insurance. None none None 10/27/2022 Clarus 7500000 None None 962.64 917.67 2020 835.00 None None
Rx0000207 Tolmar Pharmaceuticals, Inc. 12/31/2023 69087019812 Jatenza, 198 mg, 12 BOTTLES in 1 BOX, 120 Liquid Filled Capsules in 1 Bottle Brand FDA 12/09/2023 38.50 1001.15 04/12/2039 Single Source Drug 7527 None Tolmar utilizes a Pricing Committee which uses several factors to determine the price of our prescription medications.?? These include current market pricing competitiveness, existing and predicted future competition, manufacturing and distribution considerations (including distribution channel and payer model), costing including product development expenditures, profitability, and legal considerations, including compliance with rules and regulations governing sales to government and institutional purchasers.? The list price of Tolmar?s products is not reflective of discounts and rebates which may be available to patients and payers, including but not limited to, Medicaid and commercial insurance. None none None 10/27/2022 Clarus 7500000 None None 962.64 917.67 2020 835.00 None None
Rx0000207 Tolmar Pharmaceuticals, Inc. 12/31/2023 69087023712 Jatenza, 237 mg, 12 BOTTLES in 1 BOX, 120 Liquid Filled Capsules in 1 Bottle Brand FDA 12/09/2023 77.01 2002.27 04/12/2039 Single Source Drug 16577 None Tolmar utilizes a Pricing Committee which uses several factors to determine the price of our prescription medications.?? These include current market pricing competitiveness, existing and predicted future competition, manufacturing and distribution considerations (including distribution channel and payer model), costing including product development expenditures, profitability, and legal considerations, including compliance with rules and regulations governing sales to government and institutional purchasers.? The list price of Tolmar?s products is not reflective of discounts and rebates which may be available to patients and payers, including but not limited to, Medicaid and commercial insurance. None none None 10/27/2022 Clarus 7500000 None None 1925.26 1835.33 2020 1670.00 None None